ERYTECH kündigt FDA-Zulassung für seine Phase-III-Studie für Eryaspase bei Bauchspeicheldrüsenkrebs in den USA an

Matthew Durham
Omnidynamic Marketing

Joey Cohen
Medication Adherence

Matt Turner
Patient Affordability

Amy Giles
Increasing Engagement

Pat Purcell
Meeting Engagement

Suma Ramadas, PhD
Medical Affairs

Daniel Sontupe
Market Access

Brenda Snow
Authentic Patient Voice

David Linetsky
Point-of-Care Marketing

Frank Burrell
Scientific Storytelling

Paul Theisen
Patient Acquisition

Liz Kane
Impactful Strategy

Bud Bilanich
Success Coach

Stacey Gandler
Brand Nourishment